Kevin Healy,
Jan Fandrianto and Selfia Halim Distinguished Professorship in Engineering,
University of California, Berkeley
Kevin E. Healy, Ph.D. is the Jan Fandrianto and Selfia Halim Distinguished Professor in Engineering at the University of California at Berkeley in the Departments of Bioengineering, and Materials Science and Engineering. He served as Chair of the Department of Bioengineering from 2011 to 2015. He is a thought leader and innovator working at the interface between stem cells and materials science to develop dynamic engineered systems to explore both fundamental biological phenomena and new applications in translational medicine. His group currently conducts research in the areas of: bioinspired stem cell microenvironments to control stem cell lineage specification and self-organization into microtissues or organoids; bioinspired systems for regenerative medicine; biological interfaces; and, microphysiological systems for drug development, gene editing, and environmental toxicity screening. Professor Healy is an elected Fellow of AIMBE, AAAS, FBSE, BMES, and recently received an Alexander von Humboldt Foundation Award. He has chaired the Gordon Research Conference on Biomaterials and Biocompatibility, and has been honored with the 2011 Clemson award for outstanding contributions to basic biomaterials science. He is a named inventor on numerous issued United States and international patents relating to biomaterials, therapeutics, stem cells, and medical devices, and has founded several companies to develop these systems for applications in biotechnology and regenerative medicine.
Exploiting Cardiac Microphysiological Systems For COVID-19 Drug Screening
Monday, 28 September 2020 at 17:30
Add to Calendar ▼2020-09-28 17:30:002020-09-28 18:30:00Europe/LondonExploiting Cardiac Microphysiological Systems For COVID-19 Drug ScreeningPoint-of-Care Diagnostics, Global Health and Biosensors 2020 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com
Our work has emphasized creating both healthy and diseased cardiac and
liver microphysiological systems (MPS) or ‘organ chips’, to address the
costly and inefficient drug discovery process. While MPS are poised to
disrupt the drug development process and significantly reduce the cost
of bringing a new drug candidate to market, the technology is more
robust and creates a whole new paradigm in how to conduct safety
pharmacology science, and advances medicine in revolutionary ways. An
emerging use of MPS is in the evaluation of repurposed drugs to treat
COVID-19. While repurposed drugs are typically FDA-approved for
monotherapy, most have not been tested in polytherapy with
anti-inflammatory or antibiotic medications typically employed as part
of intensive care protocols. Since COVID-19 patient morbidity is highly
correlated with myocardial injury, independent of pre-existing
cardiovascular disease, this presentation will address examples of
exploiting our human cardiac MPS as unique testbeds for rapidly
assessing the cardiac liability of polytherapy of repurposed COVID-19
drugs. Preclinical data generated will inform clinical trial design for
polytherapies for COVID-19 patients, particularly regarding risks of
potential drug-drug interactions or identifying appropriate exclusion
criteria, monitoring strategies, and dose adjustments to minimize
cardiac liabilities.
Add to Calendar ▼2020-09-28 00:00:002020-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics, Global Health and Biosensors 2020Point-of-Care Diagnostics, Global Health and Biosensors 2020 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-09-28 17:30:002020-09-28 18:30:00Europe/LondonExploiting Cardiac Microphysiological Systems For COVID-19 Drug ScreeningPoint-of-Care Diagnostics, Global Health and Biosensors 2020 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com
